Method for treating ocular hypertension and glaucoma

• US 20060205725A1
• Filed: 05/23/2006
• Published: 09/14/2006
• Est. Priority Date: 10/24/2002
• Status: Active Grant

• Current Assignee: Sucampo AG Incorporated
• Original Assignee: Sucampo AG Incorporated
• Inventors: Ueno, Ryuji
• Granted Patent: US 8,673,973 B2
• Time in Patent Office: Days
• US Class Current: 514/235.500
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 47/186 Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.

Claims

1. A method for treating ocular hypertension and glaucoma, which comprises administration of an ophthalmic composition comprising latanoprost as a sole active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.

2. The method as described in claim 1, wherein the ophthalmic composition contains a dissolving agent.

3. The method as described in claim 2, wherein the dissolving agent is polysorbate 80 and/or EDTA.

4. The method as described in claim 1, wherein the concentration of benzalkonium chloride is less than 0.02%.

5. The method as described in claim 1, wherein the concentration of benzalkonium chloride is 0.01% or less.

6. The method as described in claim 1, wherein the ophthalmic composition is formulated as a single-unit dose preparation.

7. The method as described in claim 1, wherein the ophthalmic composition further comprises timolol.

8. The method as described in claim 1, wherein the ophthalmic composition is an ophthalmic solution.

18. The method as described in claim 1, wherein the ophthalmic composition contains absolutely no benzalkonium chloride.

9. A method for treating ocular hypertension and glaucoma, which comprises administration of an ophthalmic composition comprising latanoprost as a sole active ingredient thereof to a subject who has ocular hypertension and glaucoma and is in need of treatment or prevention of keratoconjunctive disorders or macular edema, wherein the ophthalmic composition contains substantially no benzalkonium chloride.

10. The method as described in claim 9, wherein the ophthalmic composition contains a dissolving agent.

11. The method as described in claim 10, wherein the dissolving agent is polysorbate 80 and/or EDTA.

12. The method as described in claim 9, wherein the concentration of benzalkonium chloride is less than 0.02%.

13. The method as described in claim 9, wherein the concentration of benzalkonium chloride is 0.01% or less.

14. The method as described in claim 9, wherein the ophthalmic composition is formulated as a single-unit dose preparation.

15. The method as described in claim 9, wherein the ophthalmic composition further comprises timolol.

16. The method as described in claim 9, wherein the ophthalmic composition is an ophthalmic solution.

19. The method as described in claim 9, wherein the concentration of benzalkonium chloride is 0.005% or less.

20. The method as described in claim 9, wherein the ophthalmic composition contains absolutely no benzalkonium chloride.

17. The method as described in claim I wherein the concentration of benzalkonium chloride is 0.005% or less.